Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Benign Prostatic Hyperplasia
Positive results from study of drug in benign prostatic hyperplasia reported
June 17th, 2005
Threshold Pharmaceuticals Inc. announced follow up results of a phase 2 study of its investigational drug candidate TH-070 (lonidamine) for the treatment of benign prostatic hyperplasia (BPH). Six months after cessation of treatment, BPH symptoms (IPSS) in patients remained significantly improved compared to baseline as were maximum urine flow, post void urine volume, and PSA. The trial, conducted in 2004 at the University of Bari, Italy, met its primary endpoint, a mean reduction in prostate volume at day 28 compared to baseline (-11.2%, p<0.001), and all other day 28 endpoints. Based on promising data from the initial dose group of patients in...
Source: Drug Week (2005-06-17)
|
